New York-based Ophelia is a telepsychiatry platform for treating opioid use disorder (OUD). The company provides online therapy and medication-assisted treatment (MAT) to reduce opioid cravings and withdrawal symptoms. Ophelia’s monthly subscription, costing USD 195 per month out of pocket, covers MAT, care team support, and virtual clinician visits via audio and video calls. Members can speak to their physician on a weekly, bi-weekly, or monthly basis.
Founded in 2019, the company offers an alternative to traditional rehab for treating OUD and claims to be a less costly option in comparison to monthly visits to a doctor and the cost of medication, which can range between USD 800 and USD 900.
In December 2021, the company concluded a USD 50 million Series B funding round led by Tiger Global Management which will be used to expand its OUD treatment solutions, grow the market reach nationwide, and develop its platform further. The proceeds will also be used to integrate with more payors and partners. The company aims to cover 80% of the OUD patients who are not engaged with the health system.
No investor data is available
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.